JP2001513822A - 免疫性凝固を調節する方法 - Google Patents
免疫性凝固を調節する方法Info
- Publication number
- JP2001513822A JP2001513822A JP54864298A JP54864298A JP2001513822A JP 2001513822 A JP2001513822 A JP 2001513822A JP 54864298 A JP54864298 A JP 54864298A JP 54864298 A JP54864298 A JP 54864298A JP 2001513822 A JP2001513822 A JP 2001513822A
- Authority
- JP
- Japan
- Prior art keywords
- fgl2
- protein
- nucleic acid
- antibody
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Transplantation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 有効量のFgl2のインヒビターをその必要のある哺乳動物に投与するこ とからなる、免疫性凝固の減少を必要とする病状の予防または治療法。 2. インヒビターがFgl2に結合する抗体である請求項1記載の方法。 3. 抗体が図5に示すアミノ酸配列を有するヒトFgl2に結合するモノクロ ーナル抗体である請求項2記載の方法。 4. 抗体が図5における位置364−378(DRYPSGNCGLYYSS G)のアミノ酸を含むヒトFgl2のエピトープに結合する請求項3記載の方法 。 5. 病状が移植片拒絶である請求項1〜4のいずれか1項記載の方法。 6. 病状が胎児喪失である請求項1〜4のいずれか1項記載の方法。 7. 動物由来の生物学的試料中においてFgl2タンパク質またはFgl2核 酸を検出することからなる、動物において免疫性凝固の増加に関する病状を診断 またはモニターする方法。 8. (a)図2または3あるいは配列番号1または3に示される配列を有する 核酸分子またはそのフラグメント、または(b)図5あるいは配列番号2または 4に示されるアミノ酸配列を有するタンパク質またはそのフラグメントを検出す ることからなる請求項7記載の方法。 9. 試料中のFgl2に結合した後に検出することができるFgl2に結合す る抗体と試料とを接触させることからなる請求項7または8記載のFgl2タン パク質を検出する方法。 10. 請求項7または8記載のFgl2をコードする核酸分子を検出する方法 であって、ハイブリダイゼーション産物の形成を可能にする条件下で該核酸分子 とハイブリダイズすることができるヌクレオチドプローブと試料とを接触させて 、ハイブリダイゼーション産物を形成させ、ハイブリダイゼーション産物をアッ セイすることからなる方法。 11. さらに、増幅配列の形成を可能にする条件下で試料をポリメラーゼ連鎖 反応において核酸分子を増幅できるプライマーで処理して、増幅配列を形成させ 、増幅配列をアッセイすることからなる請求項10記載の方法。 12. 病状が移植片拒絶である請求項7〜11のいずれか1項記載の方法。 13. 病状が胎児喪失である請求項7〜11のいずれか1項記載の方法。 14. Fgl2をコードする核酸配列またはFgl2タンパク質をその必要の ある動物に投与することからなる免疫性凝固を誘導する方法。 15. (a)図2または3あるいは配列番号1または3に示される配列を有す る核酸分子、または(b)図5あるいは配列番号2または4に示される配列を有 するタンパク質を投与することからなる請求項14記載の方法。 16. Fgl2タンパク質のプロトロンビナーゼ活性に影響を及ぼす物質をア ッセイする方法であって、基質が分解して生産物を生じることのできる条件下で 、Fgl2タンパク質、タンパク質によって分解されて生産物を生じることので きる基質および試験物質を反応させ、生産物をアッセイし、物質の不在下で得ら れた生産物と比較してタンパク質のプロトロンビナーゼ活性に対する物質の影響 を決定することからなる方法。 17. (a)Fgl2タンパク質に特異的な抗体;(b)Fgl2に対するア ンチセンスオリゴヌクレオチド;または(c)請求項16記載の方法を用いて同 定した物質と適当な希釈剤または担体を混合して含む、動物においてプロコアグ ラント活性の阻害に使用する組成物。 18. 治療上有効量の請求項17記載の組成物を投与することからなる、動物 においてプロコアグラント活性の減少を必要とする病状の予防または治療法。 19. 有効量のFgl2タンパク質またはペプチドを適当な希釈剤または担体 と混合して含む移植片拒絶を予防するためのワクチン。 20. 有効量のFgl2タンパク質またはペプチドを適当な希釈剤または担体 と混合して含む胎児喪失を予防するためのワクチン。 21. (a)図8に示される配列(ここに、TがUであることもできる); (b)(a)と実質的な配列同一性を有する核酸配列;および(c)フラグメン ト(a)または(b)を含む単離した核酸分子。 22. (a)図4に示される配列(ここに、TがUであることもできる); (b)(a)と実質的な配列同一性を有する核酸配列;および(c)フラグメン ト(a)または(b)を含む単離した核酸分子。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4653797P | 1997-05-15 | 1997-05-15 | |
US60/046,537 | 1997-05-15 | ||
US6168497P | 1997-10-10 | 1997-10-10 | |
US60/061,684 | 1997-10-10 | ||
PCT/CA1998/000475 WO1998051335A1 (en) | 1997-05-15 | 1998-05-15 | Methods of modulating immune coagulation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001513822A true JP2001513822A (ja) | 2001-09-04 |
JP4499839B2 JP4499839B2 (ja) | 2010-07-07 |
Family
ID=26724041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54864298A Expired - Fee Related JP4499839B2 (ja) | 1997-05-15 | 1998-05-15 | 免疫性凝固を調節する方法 |
Country Status (8)
Country | Link |
---|---|
US (5) | US6403089B1 (ja) |
EP (1) | EP0975361B1 (ja) |
JP (1) | JP4499839B2 (ja) |
AT (1) | ATE339964T1 (ja) |
AU (1) | AU742076B2 (ja) |
CA (1) | CA2289979C (ja) |
DE (1) | DE69835949D1 (ja) |
WO (1) | WO1998051335A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2289979C (en) * | 1997-05-15 | 2007-02-20 | Transplantation Technologies Inc. | Methods of modulating immune coagulation |
US20050175994A1 (en) * | 1999-01-20 | 2005-08-11 | Haley-Vicente Dana A. | Methods and materials relating to prothrombinase-like polypeptides and polynucleotides |
US6586390B1 (en) | 2000-01-21 | 2003-07-01 | Hyseq, Inc. | Methods and materials relating to novel prothrombinase-like polypeptides and polynucleotides |
CA2345478A1 (en) * | 2000-11-29 | 2002-05-29 | University Of Guelph | Uterine natural killer cells |
EP1448766A2 (en) * | 2001-09-27 | 2004-08-25 | University Of Delaware | Coisogenic eukaryotic cell collections |
WO2003066848A1 (en) * | 2002-02-07 | 2003-08-14 | Trillium Therapeutics Inc. | Porcine fgl2 |
US9181551B2 (en) * | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
WO2003074068A2 (en) * | 2002-03-01 | 2003-09-12 | Trillium Therapeutics Inc. | Use of soluble fgl2 as an immunosuppressant |
DE10309368A1 (de) * | 2002-08-06 | 2004-02-26 | Aventis Behring Gmbh Intellectual Property/Legal | Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase |
CA2682429A1 (en) * | 2009-05-20 | 2010-11-20 | Gary Levy | An assay for measuring plasma fgl-2 and methods and uses thereof |
US9023609B2 (en) | 2010-07-14 | 2015-05-05 | Mor Research Applications Ltd. | FGL-2 prothrombinase as a diagnostic tool for malignancy |
US9005630B2 (en) * | 2012-11-01 | 2015-04-14 | Veterinaerinstituttet | Fusion proteins for the treatment of allergic diseases |
WO2015143343A2 (en) * | 2014-03-21 | 2015-09-24 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
CN105518139B (zh) * | 2015-06-11 | 2021-02-02 | 深圳市第二人民医院 | CRISPR-Cas9特异性敲除猪FGL2基因的方法及用于特异性靶向FGL2基因的sgRNA |
WO2018204928A1 (en) * | 2017-05-05 | 2018-11-08 | Board Of Regents, The University Of Texas System | Fgl2 monoclonal antibodies and their use in treating malignant tumors |
WO2020097236A1 (en) * | 2018-11-06 | 2020-05-14 | Board Of Regents, The University Of Texas System | Fgl2 neutraling cell therapy and methods of use thereof |
CA3172608A1 (en) * | 2020-03-31 | 2021-10-07 | Ilana MANDEL | Immunosuppressing compositions comprising a fibrinigen-related domain from fibrinogen-like protein 2 and use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4834975A (en) * | 1984-05-25 | 1989-05-30 | Genetics Corporation | Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production |
IE81149B1 (en) * | 1987-02-12 | 2000-05-03 | Genentech Inc | Methods and deoxyribonucleic acid for the preparation of tissue factor protein |
US5346991A (en) * | 1991-06-13 | 1994-09-13 | Genentech, Inc. | Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders |
US5529934A (en) * | 1991-07-29 | 1996-06-25 | Biomide Investment Limited Partnership | Method for measuring blood procoagulant activity of human leukocyte antigens |
JP3337488B2 (ja) * | 1992-03-06 | 2002-10-21 | アベンティス ファーマ株式会社 | 切迫流産治療剤 |
CA2289979C (en) * | 1997-05-15 | 2007-02-20 | Transplantation Technologies Inc. | Methods of modulating immune coagulation |
-
1998
- 1998-05-15 CA CA002289979A patent/CA2289979C/en not_active Expired - Fee Related
- 1998-05-15 JP JP54864298A patent/JP4499839B2/ja not_active Expired - Fee Related
- 1998-05-15 AU AU74213/98A patent/AU742076B2/en not_active Ceased
- 1998-05-15 AT AT98921301T patent/ATE339964T1/de not_active IP Right Cessation
- 1998-05-15 WO PCT/CA1998/000475 patent/WO1998051335A1/en active IP Right Grant
- 1998-05-15 DE DE69835949T patent/DE69835949D1/de not_active Expired - Lifetime
- 1998-05-15 EP EP98921301A patent/EP0975361B1/en not_active Expired - Lifetime
-
1999
- 1999-11-15 US US09/442,143 patent/US6403089B1/en not_active Expired - Fee Related
-
2001
- 2001-07-12 US US09/902,563 patent/US6805863B2/en not_active Expired - Lifetime
-
2002
- 2002-03-13 US US10/096,255 patent/US20030103974A1/en not_active Abandoned
-
2004
- 2004-11-29 US US10/997,920 patent/US20050169913A1/en not_active Abandoned
-
2007
- 2007-01-18 US US11/654,544 patent/US20070128198A1/en not_active Abandoned
Non-Patent Citations (5)
Title |
---|
JPN6008037008, PROC NATL ACAD SCI USA, 1987, VOL.84, P.1609−1613 * |
JPN6008037011, GENE, 1995, VOL.160, P.257−262 * |
JPN6008037014, J VIROL, 1996, VOL.70, NO.7, P.4275−4282 * |
JPN6008037017, J VIROL, 1995, VOL.69, NO.8, P.5033−5038 * |
JPN6008037021, J EXP MED, 1992, VOL.176, P.689−697 * |
Also Published As
Publication number | Publication date |
---|---|
AU7421398A (en) | 1998-12-08 |
CA2289979C (en) | 2007-02-20 |
US20070128198A1 (en) | 2007-06-07 |
US6403089B1 (en) | 2002-06-11 |
US20030099654A1 (en) | 2003-05-29 |
US6805863B2 (en) | 2004-10-19 |
EP0975361B1 (en) | 2006-09-20 |
WO1998051335A1 (en) | 1998-11-19 |
US20050169913A1 (en) | 2005-08-04 |
DE69835949D1 (de) | 2006-11-02 |
ATE339964T1 (de) | 2006-10-15 |
AU742076B2 (en) | 2001-12-13 |
EP0975361A1 (en) | 2000-02-02 |
JP4499839B2 (ja) | 2010-07-07 |
US20030103974A1 (en) | 2003-06-05 |
CA2289979A1 (en) | 1998-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070128198A1 (en) | Compositions comprising antibodies to human fgl2 | |
Xia et al. | Characterization of the CAMPATH‐1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone | |
ES2281112T3 (es) | Proteina que presenta una actividad de supresion del envejecimiento. | |
CA2275141A1 (en) | Cell stress regulated human mhc class i gene | |
AU2002249948B9 (en) | Type 2 cytokine receptor and nucleic acids encoding same | |
US7462466B2 (en) | Porcine CD59 nucleic acids and cells containing the same | |
US6395882B1 (en) | Selectin ligands | |
US20070141566A1 (en) | Methods and materials relating to novel polypeptides and polynucleotides | |
KR19990022370A (ko) | 간의 재생에서 상향 조절되는 신규 유전자 | |
US20060078550A1 (en) | Porcine fgl2 | |
JP3911017B2 (ja) | 腫瘍遺伝子Int6のヌクレオチド配列及び推定アミノ酸配列 | |
EP0892807A1 (en) | Gene family associated with neurosensory defects | |
US20050208498A1 (en) | Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like protein | |
WO2001023561A2 (en) | Novel polynucleotides encoding proteins containing thrombospondin type 1 repeats | |
AU2004201169B2 (en) | Modified biological material | |
JP2005507236A (ja) | 抗原性ポリペプチドに結合する新規抗体、抗原をコードする核酸、および使用方法 | |
US20050164202A1 (en) | Materials and methods relating to therapy and diagnosis using targeting of cells that express JPL polypeptides | |
JPH08503601A (ja) | 避妊用ワクチン | |
AU2007201089A1 (en) | Modified biological material | |
WO2002032961A2 (en) | Novel polypeptides and nucleic acids encoding same | |
Morgan | Molecular Cloning and Functional | |
JP2005508604A (ja) | 抗原性ポリペプチドに結合する新規抗体、抗原をコードする核酸、および使用方法 | |
JP2005504514A (ja) | 治療用ポリペプチド、それをコードする核酸、および使用方法 | |
JP2005505247A (ja) | 治療用ポリペプチド、該ポリペプチドをコードする核酸、および使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050413 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20050413 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080805 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081104 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081205 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090310 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090608 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090717 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090710 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100209 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20100203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100212 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100330 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100416 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130423 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |